- Jiangsu Hengrui’s first quarter revenue has missed estimates.
- The revenue was recorded at 6.00 billion yuan, falling short of the estimated 6.1 billion yuan.
- There were two estimates that the calculation was based on.
- The company’s net income was at 1.37 billion yuan.
- Earnings per share (EPS) was reported at 21 RMB cents.
- In terms of recommendation trends, there are 31 “buys”, 3 “holds”, and 2 “sells”.
Jiangsu Hengrui Medicine on Smartkarma
Analyst coverage of Jiangsu Hengrui Medicine on Smartkarma by Xinyao (Criss) Wang highlights a bearish sentiment on the company. In the research report titled “China Healthcare Weekly (Mar.1) – Prioritize Big Pharma, Real Ownership of Pricing Power, Hengrui,” Wang advises investors to prioritize pharmaceutical companies with abundant cash flow and biotech firms with diversified funding sources for higher safety margins. The report suggests that pricing power in the industry ultimately rests with consumers, not enterprises. Wang points out that Hengrui is deemed overvalued in the current challenging environment, citing factors such as the presence of around RMB5 billion generic drugs yet to enter the VBP scope.
A look at Jiangsu Hengrui Medicine Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 5 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Investors looking at Jiangsu Hengrui Medicine will find a company with a strong long-term outlook. Smartkarma Smart Scores rate the company highly in Resilience, indicating its ability to weather economic uncertainties. The company also scores well in Growth and Momentum, showcasing positive trends in its development and market performance. With a focus on developing, manufacturing, and marketing a range of essential medicines and packing materials, Jiangsu Hengrui Medicine is positioned to capitalize on the growing healthcare sector.
Jiangsu Hengrui Medicine‘s average scores in Value and Dividend highlight areas where improvement could drive further investor interest. However, the company’s solid performance in key areas positions it well for sustained growth and market presence in the pharmaceutical industry. Overall, Jiangsu Hengrui Medicine shows promise as a resilient player with momentum and growth potential in the long term.
Summary: Jiangsu Hengrui Medicine Co., Ltd. specializes in developing, producing, and selling various medicines and medicine packing materials, including anti-tumor medicines, pain-killers, anti-infection medicines, and aluminum foil products among others.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
